An enzyme-powered microRNA discriminator for the subtype-specific diagnosis of breast cancer

Mao, Huiru; Cao, Ya; Zou, Zihan; Xia, Jianan; Zhao, Jing

doi:10.1039/d3sc00090g

Cited by 10 publications

(11 citation statements)

References 49 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this method is time‐consuming and exhibits limits of detection at the sub‐pM level. Alternatively, Zhao's group [26] reported enzyme‐assisted DNA signal amplification for cancer subtyping based on an electrochemical technique (Figure 2b). The miRNA discriminator was involved in two TMSD reactions, in which two miRNA biomarkers (miR21 and miR210) initiated strand displacement sequentially and a T7 exonuclease (EXO) powered digestion procedure.…”

Section: Cellular Biomarker For Differentiating Subtypes Of Cancer Ba...mentioning

confidence: 99%

“…(a) MALDI-MS for simultaneously detecting multiple miRNA biomarkers from the subtypes of different breast cancers [25]. (b) Enzyme-driven miRNA detection with the electrochemical measurement in the subtype profiling of breast cancer cells [26]. Graph copyright from reference[25,26] .…”

mentioning

confidence: 99%

“…(b) Enzyme-driven miRNA detection with the electrochemical measurement in the subtype profiling of breast cancer cells [26]. Graph copyright from reference[25,26] .…”

mentioning

confidence: 99%

See 2 more Smart Citations

Smart DNA sensors‐based molecular identification for cancer subtyping

Gao,

Xiong,

Gong

et al. 2023

Smart Molecules

View full text Add to dashboard Cite

Molecular subtyping of cancer can greatly help to understand the development of disease and predict tumor behavior. Exploring detection methods for precise subtyping is appealing to prognosis and personalized therapy. During the past decades, DNA‐based biosensors have exhibited great potential in cancer diagnosis due to their structural programmability and functional diversity. Despite the encouraging progress that has been made, there remains an issue in improving the accuracy and sensitivity of cancer subtyping due to the complex process of disease, especially in preclinical or clinical applications. To accelerate the development of DNA sensors in the identification of cancer subtypes, in this review, we summarized their advances in molecular subtyping by analyzing the heterogeneity in categories and levels of biomarkers between cancer subtypes. The strategies toward genomic and proteomic heterogeneity in cells or on the cell surface, as well as the cancer excretions including extracellular vesicles (EVs) and microRNA (miRNAs) in serum, are summarized. Current challenges and the opportunities of DNA‐based sensors in this field are also discussed.

show abstract

Section: Cellular Biomarker For Differentiating Subtypes Of Cancer Ba...mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Smart DNA sensors‐based molecular identification for cancer subtyping

Gao,

Xiong,

Gong

et al. 2023

Smart Molecules

View full text Add to dashboard Cite

show abstract

“…Extensive investigations have consistently demonstrated that miRNAs hold great potential to serve as vigorous biomarkers for cancer diagnosis. [4][5][6] Various strategies have been reported for the detection of miRNAs in vitro and within living cells. [7][8][9] However, it is important to acknowledge that there is usually a variety of miRNAs with abnormal expression in a particular cancer, and the dysregulation of a single miRNA may be related to multiple cancers.…”

mentioning

confidence: 99%

“…Extensive investigations have consistently demonstrated that miRNAs hold great potential to serve as vigorous biomarkers for cancer diagnosis. 4–6…”

mentioning

confidence: 99%

High-fidelity intracellular imaging of multiple miRNAs via stimulus-responsive nanocarriers and catalytic hairpin assembly

Zhang,

Liu,

Zhang

et al. 2024

Chem. Commun.

View full text Add to dashboard Cite

show abstract

Quantitative Imaging of MicroRNA‐21 In Vivo for Real‐Time Monitoring of the Cancer Initiation and Progression

Zheng,

Wu,

Wang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

MicroRNA‐21 (MiR‐21) has been confirmed to be upregulated in tumors, and its abnormal expression is closely associated with tumor occurrence. However, the traditional imaging methods are limited to qualitative imaging of miR‐21, and no effective strategy has been developed for monitoring its concentration in vivo during cancer initiation and progression. Herein, a biosensor is created utilizing a NIR‐II ratiometric fluorescent nanoprobe to quantitatively monitor dynamic alterations in miR‐21 levels in vivo. The nanoprobe (termed DCNP@DNA2@IR806) is constructed by introducing IR806 as a donor and down‐conversion nanoparticles (DCNP) as the acceptor, using DNA as linkers. Upon miR‐21‐responsive initiation of the nanoprobe, the 1550 nm fluorescent signal of DCNP stimulated by a 808 nm laser (F1550, 808Ex) increased because of the close proximity of IR806 to the DCNP and the subsequent non‐radiative energy transfer (NRET). Meanwhile, the 1550 nm fluorescent signal of DCNP stimulated by a 980 nm laser (F1550, 980Ex) remained stable because of the absence of NRET. This ratiometric NIR‐II fluorescent signal has been confirmed to be a reliable indicator of miR‐21 concentration in vivo. The strategy holds promise for further enhancing the understanding of microRNAs‐based molecular mechanisms underlying cancer progression, laying a foundation for the early diagnosis of microRNAs‐related diseases.

show abstract

An enzyme-powered microRNA discriminator for the subtype-specific diagnosis of breast cancer

Abstract: This paper reports an enzyme-powered microRNA discriminator to selectively distinguish breast cancer cells from normal cells and further identify subtype-specific features.

Cited by 10 publications

References 49 publications

Smart DNA sensors‐based molecular identification for cancer subtyping

Smart DNA sensors‐based molecular identification for cancer subtyping

High-fidelity intracellular imaging of multiple miRNAs via stimulus-responsive nanocarriers and catalytic hairpin assembly

Quantitative Imaging of MicroRNA‐21 In Vivo for Real‐Time Monitoring of the Cancer Initiation and Progression

Contact Info

Product

Resources

About